GlassScriptPhysician profile
Steven T Margolis
NPI 1619931268
$89,874.16
in general payments reported to CMS, 2019-2025
42 companies · $12K in 2025
The $12K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54K · 2020: $7,723 · 2021: $7,732 · 2022: $2,194 · 2023: $3,905 · 2024: $2,464 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,906 · Food and Beverage: $7,718 · Travel and Lodging: $1,396 · Honoraria: $1,075 · Consulting Fee: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,905.76 |
| Food and Beverage | $7,717.53 |
| Travel and Lodging | $1,395.87 |
| Honoraria | $1,075.00 |
| Consulting Fee | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $31,553.50 | 2019-2023 | |
| Amgen INC. | $15,594.94 | 2019-2025 | Repatha, Repatha, Evenity |
| Kowa Pharmaceuticals America, INC. | $13,936.98 | 2019-2025 | Zoryve, Livalo, Seglentis |
| Madrigal Pharmaceuticals | $9,100.99 | 2024-2025 | Rezdiffra, Resmetirom |
| Esperion Therapeutics, INC. | $8,278.48 | 2020-2025 | Nexletol, Nexlizet |
| Medicure Pharma INC. | $1,860.71 | 2019-2024 | Zypitamag |
| Abbvie INC. | $1,720.17 | 2021-2025 | |
| Lilly USA, LLC | $1,436.76 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Chiesi USA, INC. | $1,115.96 | 2025 | Juxtapid |
| Novo Nordisk INC | $1,096.36 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $847.01 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $457.66 | 2019-2025 | Evkeeza |
| Astrazeneca Pharmaceuticals LP | $377.47 | 2019-2023 | Farxiga |
| Corcept Therapeutics | $312.18 | 2019-2023 | Korlym |
| Glaxosmithkline, LLC. | $244.06 | 2022-2024 | Shingrix, Trelegy Ellipta, Arexvy |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Margolis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.